Deciphera Pharmaceuticals, Inc. (DCPH) is a publicly traded company in the Unknown sector. Across all available filings, 16 corporate insiders have executed 401 transactions totaling $162.0M, demonstrating a bearish sentiment with -$46.4M in net insider flow. The most recent transaction on Apr 22, 2024 involved a transaction of 48,136 shares valued at $0.
No significant insider buying has been recorded for DCPH in the recent period.
No significant insider selling has been recorded for DCPH in the recent period.
Based on recent SEC filings, insider sentiment for DCPH is bearish with an Insider Alignment Score of 36/100 and a net flow of -$46.4M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Deciphera Pharmaceuticals, Inc. (DCPH) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 16 insiders are actively trading DCPH stock, having executed 401 transactions in the past 90 days. The most active insider is Associates Llc Brightstar (Executive), who has made 6 transactions totaling $44.8M.
Get notified when executives and directors at DCPH file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Apr 22, 2024 | Llc Brightstar Associates | Executive | Exercise | 48,136 | $N/A | $0 | |
| Feb 16, 2024 | Pitman Jama | Executive | Sale | 2,267 | $15.62 | $35.4K | |
| Feb 16, 2024 | L. Sherman Matthew | Executive | Sale | 2,615 | $15.62 | $40.8K | |
| Feb 16, 2024 | C. Martin Daniel | Executive | Sale | 2,267 | $15.62 | $35.4K | |
| Feb 16, 2024 | Patrick Kelly Thomas | Executive | Sale | 3,010 | $15.62 | $47.0K | |
| Feb 15, 2024 | Pitman Jama | Executive | Award | 10,000 | $N/A | $0 | |
| Feb 15, 2024 | Pitman Jama | Executive | Award | 9,725 | $N/A | $0 | |
| Feb 15, 2024 | L. Sherman Matthew | Executive | Award | 17,275 | $N/A | $0 | |
| Feb 15, 2024 | C. Martin Daniel | Executive | Award | 9,725 | $N/A | $0 | |
| Feb 15, 2024 | Dhanak Dashyant | Executive | Award | 17,275 | $N/A | $0 | |
| Feb 15, 2024 | Patrick Kelly Thomas | Executive | Award | 17,275 | $N/A | $0 | |
| Feb 7, 2024 | Llc Brightstar Associates | Executive | Exercise | 914,001 | $N/A | $0 | |
| Jan 16, 2024 | C. Martin Daniel | Executive | Sale | 1,624 | $14.47 | $23.5K | |
| Jan 16, 2024 | Patrick Kelly Thomas | Executive | Sale | 2,435 | $14.47 | $35.2K | |
| Jan 16, 2024 | Pitman Jama | Executive | Sale | 1,624 | $14.47 | $23.5K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 224 | $104.2M | 61.8% |
Purchase(P) | 6 | $57.8M | 34.3% |
Exercise(M) | 99 | $5.7M | 3.4% |
Payment(F) | 9 | $764.4K | 0.5% |
Conversion(C) | 13 | $98.8K | 0.1% |
Exercise (Options)(X) | 3 | $0 | 0.0% |
Award(A) | 43 | $0 | 0.0% |
Gift(G) | 4 | $0 | 0.0% |
Insider selling pressure at Deciphera Pharmaceuticals, Inc. has increased, with 16 insiders executing 401 transactions across all time. Total sales of $104.2M significantly outpace purchases of $57.8M, resulting in a net outflow of $46.4M. This selling activity appears largely discretionary, which may warrant closer attention from investors.